Annual Reports in Medicinal Chemistry

<p>Section I: Central Nervous System Diseases – ROBICHAUD</p> <ol> <p> <li>Voltage-Gated Calcium Channel Antagonists for the Central Nervous System</li> <p>James C. Barrow and Joseph L. Duffy</p> <p> <li>Recent Developments in Glycine Transporter-1 Inhibitors</li> <p>Christopher L. Cioffi, Shuang Liu and Mark A.Wolf</p> <p> <li>Modulators of Transient Receptor Potential Ion Channels</li> <p>Rajagopal Bakthavatchalam and S. David Kimball</p> <p> <li>Defining Neuropharmacokinetic Parameters in CNS Drug Discovery to Determine Cross-species Pharmacologic Exposure-Response Relationships</li> <p>Christopher L. Shaffer</p> <p>Section II: Cardiovascular and Metabolic Diseases - STAMFORD</p> <p> <li>High Affinity Niacin Receptor GPR109A Agonists</li> <p>Hong C. Shen and Steven L. Colletti</p> <p> <li>Recent Advances in Acetyl CoA Carboxylase (ACC) Inhibitors</li> <p>Matthew P. Bourbeau, John G. Allen, and Wei Gu</p> <p> <li>Enzymatic Targets in the Triglyceride Synthesis Pathway</li> <p>Dmitry O. Koltun and Jeff Zablocki</p> <p> <li>Inhibitors of HIF Prolyl Hydroxylases</li> <p>Michael H. Rabinowitz, Terrance D. Barrett, Mark D. Rosen, Hariharan Venkatesan</p> <p>Section III: Inflammation / Pulmonary / GI - BARRISH/Weinstein</p> <p> <li>Opioid Receptor Antagonists for Gastrointestinal Dysfunction</li> <p>R. William Hipkin and Roland E. Dolle</p> <p> <li>CFTR Modulators for the Treatment of Cystic Fibrosis</li> <p>Sabine Hadida, Frederick Van Goor and Peter D. J. Grootenhuis</p> <p> <li>Targeting B-cells in inflammatory disease</li> <p>Kevin S. Currie</p> <p> <li>Modulators of Toll-Like Receptor (TLR) Signaling</li> <p>Mark Spyvee, Lynn Hawkins, and Sally Ishizaka</p> <p>Section IV: Oncology - McAlpine</p> <p> <li>Janus Kinase 2 (JAK2) inhibitors for the treatment of myeloproliferative neoplasm (MPN)</li> <p>Ashok V. Purandare, Matthew V. Lorenzi and Louis J. Lombardo</p> <p> <li>Development of poly(ADP-ribose)polymerase (PARP) inhibitors in oncology</li> <p>Philip Jones</p> <p> <li>Epigenetic Targets and Cancer Drug Discovery</li> <p>Patrick M. Woster, Ph.D</p> <p>Section V: Infectious Diseases - Primeau</p> <p> <li>HIV-1 Integrase Strand Transfer Inhibitors</li> <p>Brian A. Johns</p> <p> <li>Recent Advances in Drug Discovery for Neglected Tropical Diseases Caused by Infective Kinetoplastid Parasites</li> <p>Robert T. Jacobs and Charles Ding</p> <p> <li>Recent Advances in the Inhibition of Bacterial Fatty Acid Biosynthesis</li> <p>Vincent Gerusz</p> <p>Section VI: Topics in Biology - LOWE</p> <p> <li>Back to the Plaque: Emerging Studies That Re-Focus Attention on the Neuritic Plaque in Alzheimer’s Disease</li> <p>Dr. Robert B. Nelson</p> <p> <li>Targeting Methyl Lysine</li> <p>Stephen V. Frye, Tom Heightman and Jian Jin</p> <p> <li>Chemical Proteomic Technologies for Drug Target Identification</li> <p>Kieran F. Geoghegan and Douglas S. Johnson</p> <p> <li>NIH Translational Programs for Assisting Pre-Clinical Drug Discovery and Development</li> <p>Raj N. Misra</p> <p>Section VII: Topics in Drug Design and Discovery - DESAI</p> <p> <li>Role of Physicochemical Properties and Lipophilic Ligand Efficiency (LipE or LLE) in addressing Drug Safety Risks</li> <p>Martin P. Edwards and David A. Price</p> <p> <li>Reducing the Risk of Drug Attrition Associated with Physicochemical Properties</li> <p>Paul D. Leeson and James R. Empfield</p> <p> <li>Compound Collection Enhancement and Paradigms for High Throughput Screening - an Update</li> <p>Stevan W Djuric, Irini Akritopoulou-Zanze, Philip B Cox and Scott Galasinski</p> <p> <li>The Role of Fluorine in the Discovery and Optimization of CNS Agents: Modulation of Drug-Like Properties</li> <p>Kevin J. Hodgetts, Kerry J. Combs, Amy M. Elder and Geraldine C. Harriman</p> <p> <li>Patents in Drug Discovery: Case Studies, Examples, and Simple Steps Medicinal Chemists Can Take to Protect Hard-Won Intellectual Property</li> <p>Charles J. Andres, Jr. and Richard L. Treanor</p> <p>Section VIII: Trends and Perspectives</p> <p> <li>To Market, To Market – 2009</li> </ol> <p>Shridhar Hegde and Michelle Schmidt</p>